TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07752472: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PSTC100 in Healthy Adult Subjects

Sponsor: Prospect Therapeutics (Nanjing) Limited · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 70 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07752472 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07752472 Rescue Dossier →